Stephen Ronan Ferguson

Amministratore Delegato presso Medix Biochemica Oy Ab

Health Technology

Profilo

Stephen Ronan Ferguson currently works at Medix Biochemica Oy Ab, as Chief Executive Officer from 2020, Medix Biochemica Group Oy, as Chief Executive Officer from 2020, and Diaclone SAS, as Chairman from 2021.

Posizioni attive di Stephen Ronan Ferguson

Società	Posizione	Inizio
Medix Biochemica Oy Ab Medix Biochemica Oy Ab Medical SpecialtiesHealth Technology Medix Biochemica Oy Ab develops, produces, and markets monoclonal antibodies, antibody services, and recombinant antigens for in vitro diagnostics industry. It also provides rapid tests for human healthcare. The company was founded in 1985 and is headquartered in Espoo, Finland.	Amministratore Delegato	01/01/2020
Diaclone SAS Diaclone SAS BiotechnologyHealth Technology Part of Medix Biochemica Group Oy, Diaclone SAS is a French company that specializes in clinical immunology and cell diagnoses. The company is based in Besançon, France. Diaclone was acquired by Medix Biochemica Oy Ab from Biotech Investissement SAS on July 13, 2021.	Presidente	28/07/2021
Medix Biochemica Group Oy Medix Biochemica Group Oy BiotechnologyHealth Technology Medix Biochemica Group Oy engages in business and management consultancy activities. The company was founded on January 23, 2018 and is headquartered in Helsinki, Finland.	Amministratore Delegato	01/01/2020

Tutte le posizioni attive di Stephen Ronan Ferguson

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Stephen Ronan Ferguson

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	3
Diaclone SAS Diaclone SAS BiotechnologyHealth Technology Part of Medix Biochemica Group Oy, Diaclone SAS is a French company that specializes in clinical immunology and cell diagnoses. The company is based in Besançon, France. Diaclone was acquired by Medix Biochemica Oy Ab from Biotech Investissement SAS on July 13, 2021.	Health Technology
Medix Biochemica Oy Ab Medix Biochemica Oy Ab Medical SpecialtiesHealth Technology Medix Biochemica Oy Ab develops, produces, and markets monoclonal antibodies, antibody services, and recombinant antigens for in vitro diagnostics industry. It also provides rapid tests for human healthcare. The company was founded in 1985 and is headquartered in Espoo, Finland.	Health Technology
Medix Biochemica Group Oy Medix Biochemica Group Oy BiotechnologyHealth Technology Medix Biochemica Group Oy engages in business and management consultancy activities. The company was founded on January 23, 2018 and is headquartered in Helsinki, Finland.	Health Technology

Vedi le connessioni aziendali